Strategic Partnerships GemPharmatech has formed high-profile collaborations with MSK and GCCL to provide integrated preclinical solutions and in vivo efficacy testing, signaling appetite for global co-development and expanded service offerings that can be monetized through joint projects and licensing opportunities.

Global Expansion Recent MOUs and international partnerships indicate a growth trajectory beyond domestic markets, presenting upsell potential for cross-border studies, customized mouse model supply, and phenotype screening services to pharmaceutical and biotech companies worldwide.

Advanced Models With NeoMab and a broad repository of humanized mouse strains, GemPharmatech can target antibody discovery, immuno-oncology, and therapeutic antibody development programs, offering specialized model services to accelerate preclinical timelines.

Funding & Growth Previous financing rounds and a reported revenue range position GemPharmatech as a scale-ready partner, making it suitable for strategic investments, co-development deals, or enterprise services contracts with mid-to-large biotech firms.

Integrated Services One-stop offerings from model customization to pharmacology create cross-sell opportunities to clients seeking end-to-end preclinical pipelines, enabling upsell of phenotyping, pharmacology testing, and bespoke model generation under bundled engagements.